Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Abstract There is an urgent need to understand the nature of immune responses generated against SARS-CoV-2, to better inform risk-mitigation strategies for people living with HIV (PLWH). Although not all PLWH are considered immunosuppressed, residual cellular immune deficiency and ongoing inflammation could influence COVID-19 disease severity, the evolution and durability of protective memory responses. Here, we performed an integrated analysis, characterizing the nature, breadth and magnitude of SARS-CoV-2-specific immune responses in PLWH, controlled on ART, and HIV negative subjects. Both groups were in the convalescent phase of predominately mild COVID-19 disease. The majority of PLWH mounted SARS-CoV-2 Spike- and Nucleoprotein-specific antibodies with neutralizing activity and SARS-CoV-2-specific T cell responses, as measured by ELISpot, at levels comparable to HIV negative subjects. T cell responses against Spike, Membrane and Nucleocapsid were the most prominent, with SARS-CoV-2-specific CD4 T cells outnumbering CD8 T cells. Notably, the overall magnitude of SARS-CoV-2-specific T cell responses related to the size of the naive CD4 T cell pool and the CD4:CD8 ratio in PLWH, in whom disparate antibody and T cell responses were observed. Both humoral and cellular responses to SARS-CoV-2 were detected at 5-7 months post-infection, providing evidence of medium-term durability of responses irrespective of HIV serostatus. Incomplete immune reconstitution on ART and a low CD4:CD8 ratio could, however, hamper the development of immunity to SARS-CoV-2 and serve as a useful tool for risk stratification of PLWH. These findings have implications for the individual management and potential effectiveness of vaccination against SARS-CoV-2 in PLWH.One Sentence Summary Adaptive immune responses to SARS-CoV-2 in the setting of HIV infection.
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 17. Dez. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alrubayyi, Aljawharah [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2021.02.15.431215 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI019954719 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI019954719 | ||
| 003 | DE-627 | ||
| 005 | 20230429100837.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210217s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.02.15.431215 |2 doi | |
| 035 | |a (DE-627)XBI019954719 | ||
| 035 | |a (biorXiv)10.1101/2021.02.15.431215 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alrubayyi, Aljawharah |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract There is an urgent need to understand the nature of immune responses generated against SARS-CoV-2, to better inform risk-mitigation strategies for people living with HIV (PLWH). Although not all PLWH are considered immunosuppressed, residual cellular immune deficiency and ongoing inflammation could influence COVID-19 disease severity, the evolution and durability of protective memory responses. Here, we performed an integrated analysis, characterizing the nature, breadth and magnitude of SARS-CoV-2-specific immune responses in PLWH, controlled on ART, and HIV negative subjects. Both groups were in the convalescent phase of predominately mild COVID-19 disease. The majority of PLWH mounted SARS-CoV-2 Spike- and Nucleoprotein-specific antibodies with neutralizing activity and SARS-CoV-2-specific T cell responses, as measured by ELISpot, at levels comparable to HIV negative subjects. T cell responses against Spike, Membrane and Nucleocapsid were the most prominent, with SARS-CoV-2-specific CD4 T cells outnumbering CD8 T cells. Notably, the overall magnitude of SARS-CoV-2-specific T cell responses related to the size of the naive CD4 T cell pool and the CD4:CD8 ratio in PLWH, in whom disparate antibody and T cell responses were observed. Both humoral and cellular responses to SARS-CoV-2 were detected at 5-7 months post-infection, providing evidence of medium-term durability of responses irrespective of HIV serostatus. Incomplete immune reconstitution on ART and a low CD4:CD8 ratio could, however, hamper the development of immunity to SARS-CoV-2 and serve as a useful tool for risk stratification of PLWH. These findings have implications for the individual management and potential effectiveness of vaccination against SARS-CoV-2 in PLWH.One Sentence Summary Adaptive immune responses to SARS-CoV-2 in the setting of HIV infection | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Gea-Mallorquí, Ester |e verfasserin |4 aut | |
| 700 | 1 | |a Touizer, Emma |e verfasserin |4 aut | |
| 700 | 1 | |a Hameiri-Bowen, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Kopycinski, Jakub |e verfasserin |4 aut | |
| 700 | 1 | |a Charlton, Bethany |e verfasserin |4 aut | |
| 700 | 1 | |a Fisher-Pearson, Natasha |e verfasserin |4 aut | |
| 700 | 1 | |a Muir, Luke |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, Annachiara |e verfasserin |4 aut | |
| 700 | 1 | |a Roustan, Chloe |e verfasserin |4 aut | |
| 700 | 1 | |a Earl, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Cherepanov, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Pellegrino, Pierre |e verfasserin |4 aut | |
| 700 | 1 | |a Waters, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Fiona |e verfasserin |4 aut | |
| 700 | 1 | |a Kinloch, Sabine |e verfasserin |4 aut | |
| 700 | 1 | |a Dong, Tao |e verfasserin |4 aut | |
| 700 | 1 | |a Dorrell, Lucy |e verfasserin |4 aut | |
| 700 | 1 | |a Rowland-Jones, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a McCoy, Laura E. |e verfasserin |4 aut | |
| 700 | 1 | |a Peppa, Dimitra |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 17. Dez. |
| 773 | 1 | 8 | |g year:2022 |g day:17 |g month:12 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s41467-021-26137-7 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.02.15.431215 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 17 |c 12 | ||